A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib
NCT05665192 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150
Last updated 2025-04-08
Summary
The purpose of this study is to determine real-world patient-reported outcomes with fedratinib (FEDR) therapy for myelofibrosis (MF) in the real-world (RW) setting.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-08-02
- Primary Completion
- 2023-07-24
- Completion
- 2023-07-24
Countries
- United States
Study Locations
More Related Trials
-
Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis
NCT03373877 ·Status: TERMINATED ·Phase: PHASE1
-
A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome
NCT02400463 ·Status: COMPLETED ·Phase: PHASE2
-
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
NCT00509899 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg
NCT02742324 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis
NCT06619522 ·Status: WITHDRAWN ·Phase: PHASE2
-
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
NCT03935555 ·Status: TERMINATED ·Phase: PHASE1
-
Safety and Efficacy of Ruxolitinib for COVID-19
NCT04348071 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids
NCT03616184 ·Status: COMPLETED ·Phase: PHASE2
-
Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis
NCT06951971 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
NCT04551131 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial
NCT00934544 ·Status: COMPLETED ·Phase: PHASE3
-
Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.
NCT02038036 ·Status: COMPLETED ·Phase: PHASE3
-
A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
NCT06019728 ·Status: COMPLETED ·Phase: PHASE4
-
DEP-Ru Regimen as a Salvage Therapy for HLH
NCT03533790 ·Status: UNKNOWN ·Phase: PHASE3
-
Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)
NCT05762640 ·Status: RECRUITING ·Phase: PHASE2
-
Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis
NCT04120090 ·Status: UNKNOWN ·Phase: PHASE3
-
Ruxolitinib Combined With Dexamethasone for HLH
NCT03795909 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Ruxolitinib to Combat COVID-19
NCT04354714 ·Status: WITHDRAWN ·Phase: PHASE2
-
Mirdametinib in Histiocytic Disorders
NCT06153173 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease
NCT06462469 ·Status: RECRUITING ·Phase: PHASE4
-
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
NCT06034002 ·Status: RECRUITING ·Phase: PHASE1
-
Combination of JAK2 Inhibitor and Erythropoiesis-stimulating Agent in Myelofibrosis
NCT03208803 ·Status: COMPLETED
-
Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis
NCT06201715 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome
NCT02390362 ·Status: TERMINATED ·Phase: PHASE3
-
Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis
NCT00275613 ·Status: COMPLETED ·Phase: PHASE1